The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium, a new consortium co-led by investigators from Weill Cornell Medicine; the University of California, San Francisco; Johns Hopkins Medicine; and Vanderbilt University Medical Center. The grant, awarded in March 2024, aids the PreDicTR consortium with aims to accelerate the identification and development of new TB regimens for future clinical testing.

The PreDiCTR consortium, which brings together over 30 multidisciplinary investigators from 20 institutions globally, is led by four co-principal investigators, Dirk Schnappinger, PhD, of Well Cornell Medicine; Rada Savic, PhD, of the University of California; San Francisco; Kelly Dooley, MD, PhD, MPH, of Vanderbilt University; and Eric Nuermberger, MD of Johns Hopkins University.